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INTRODUCTION
Lung cancer is the leading cause of cancer mortality world-
wide (1). The overall 5-yr survival for lung cancer is approx-
imately 15% and has improved only marginally over the
past 30 yr despite the progress of modern chemotherapy (2).
Therefore, new treatment strategies are needed to improve
the prognosis of this dismal disease. 
Aberrant signaling from the epidermal growth factor recep-
tor (EGFR) is known to be important in the development
and progress of non-small-cell lung cancer (NSCLC) (3). Sev-
eral agents designed to inhibit EGFR tyrosine kinase such
as gefitinib and erlotinib showed good tolerability and anti-
tumor activity in NSCLC (4, 5). Somatic mutations in the
region of EGFR encoding the tyrosine kinase domain have
been identified to be an important factor determining the
sensitivity to these drugs (6, 7). The tyrosine kinase domain
of EGFR consists of N and C lobes. Until now, mutations
had been found in EGFR exons 18-21, which encode the N
lobe and part of the C lobe. Mutations in the different exons
target structures around the ATP-binding cleft of EGFR,
including the phosphate-binding loop (P-loop), the  C-helix,
and the activation loop (A-loop) (8). In theory, all mutations
could result in conformational changes and increased activity
of the protein, as well as changes in its sensitivity to tyrosine
kinase inhibitors (TKI) (6, 7, 9).
Recent studies have reported inconsistent results for EGFR
mutations as a prognostic factor in cancer. The Canadian
BR.21 trial reported that the presence of EGFR mutations
confers no survival benefit on patients treated with erlotinib,
whereas the results of the TRIBUTE trial found that EGFR
mutations are a good prognostic factor (10-14). We surmised
that there might be subgroups of EGFR mutations showing
different survival rates.
KRAS mutations, which could result in resistance to EGFR
inhibitors, are frequently reported changes in the EGFR sig-
naling pathway in NSCLC (15, 16). These mutations are
detected in 15-20% of NSCLC patients (16). A recent meta-
analysis suggested that KRAS mutations might be another
prognostic factor for overall survival in NSCLC (17).
We undertook this study to identify a subgroup of EGFR
mutations and to define the prognostic role of KRAS muta-
tions involved in the overall survival of patients with resect-
ed NSCLC.
PATIENTS AND METHODS
Patients
Tumor tissues were procured from patients who had under-
gone surgical resection at the Korea Cancer Center Hospital
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Clinical Features Reflect Exon Sites of EGFR Mutations in Patients
with Resected Non-Small-Cell Lung Cancer
The aim of the current study was to determine the clinical significance according to
the subtypes of epidermal growth factor receptor (EGFR) mutations and presence of
KRAS mutations in operable non-small-cell lung cancer (NSCLC). We sequenced
exons 18-21 of the EGFR tyrosine kinase domain and examined mutations in codons
12 and 13 of KRAS in tissues of patients with NSCLC who had undergone surgical
resection. EGFR mutations were more frequent in never-smokers than smokers
(33% vs. 14%, respectively; p=0.009) and in females than in males (31% vs. 16%,
respectively; p=0.036). Mutations in exon 18-19 and 20-21 were found in 10 and
22 patients, respectively. Never-smokers and broncho-alveolar cell carcinoma fea-
tures were positively associated with a mutation in exon 18-19 (p=0.027 and 0.016,
respectively). The five-year survival rate in patients with a mutation in exons 18-19
(100%) was higher than that in patients without such mutation (47%; p=0.021). KRAS
mutations were found in 16 patients (12%) and were not related to the overall sur-
vival (p=0.742). Patients with an EGFR mutation in exons 18-19 had better survival
than patients without such mutation. Subtypes of EGFR mutations may be prognos-
tic factors in patients undergoing curative resection. 
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from May 1995 to May 2004. One hundred and thirty three
formalin-fixed paraffin-embedded tissues were available for
the analysis. All patients had pathologically proven localized
NSCLC. All pathology was reviewed using the WHO clas-
sification (18). Pure broncho-alveolar cell carcinoma (BAC),
BAC with focal invasion, and adenocarcinoma with BAC
features were considered as one entity (adenocarcinoma with
BAC features) (19, 20). The study protocol was reviewed and
approved by the institutional review board of the Korea Can-
cer Center Hospital.
DNA Sequencing for EGFR and KRAS mutations
DNA was extracted from formalin-fixed paraffin-embed-
ded tissue sections of 10  m thickness. DNA (100 ng) was
amplified in 20  L of reaction solution containing 2  L of
10× buffer (Roche, Mannheim, Germany), 1.7-2.5 mM/L
MgCl2, 250  M deoxynucleoside triphosphate, 2.5 units of
DNA polymerase (Roche), and 0.3  M each primer pair for
EGFR (exon 18: forward, 5′ -TCCAAATGAGCTGGCAA-
GTG-3′ and reverse, 5′ -TCCCAAACACTCAGTGAAAC-
AAA-3′ ; exon 19: forward, 5′ -ATGTGGCACCATCTCAC-
AATTGCC-3′ and reverse, 5′ -CCACACAGCAAAGCAG-
AAACTCAC-3′ ; exon 20: forward, 5′ -CATTCATGCGTC-
TTCACCTG-3′ and reverse, 5′ -CATATCCCCATGGCAA-
ACTC-3′ ; exon 21: forward, 5′ -GCTCAGAGCCTGGCA-
TGAA-3′ and reverse, 5′ -CATCCTCCCCTGCATGTGT-
3′ ) or KRAS (codons 12-13: forward, 5′ -TTATGTGTGAC-
ATGTTCTAAT-3′ and reverse, 5′ -AGAATGGTCCTGC-
ACCAGTAA-3′ ; codon 61: forward, 5′ -TCAAGTCCTTT-
GCCCATTTT-3′ and reverse, 5′ -TGCATGGCATTAGCA-
AAGAC-3′ ). Fragments were amplified with a 5 min initial
denaturation at 94℃, followed by 30 cycles of 1 min at 94℃,
1 min at 57℃ (EGFR mutation) or 55℃ (KRAS mutation),
and 1 min at 72℃, with a final 10 min extension at 72℃.
Purification and sequencing were performed as previously
described (13).
Statistical analysis
The primary endpoint was overall survival, the definition
of which was the time from diagnosis to death from any cause.
The secondary endpoint was disease-free survival, which was
defined as the time from diagnosis to the earliest occurrence
of relapse or death from any cause. Overall and disease-free
survivals were calculated by the Kaplan-Meier method (21).
The Pearson  2 or Fisher’s exact test was used for categorical
variables. Mutation type (wild type, mutations in exons 18-
19 or 20-21) was correlated with sex, smoking history, and
pathology using multinomial logistic regression with the mu-
tation type as the categorical dependent variable. A log-rank
test was performed for the univariate analysis of survival.
Recursive partitioning using RPART, with exponential
scaling for survival data, was applied to classify patients accord-
ing to their death risk (22, 23). The splitting process stopped
when the number of splits was two to avoid overfitting.
S-PLUS
�was used for statistical analyses. All pvalues report-
ed are the results of two-sided tests, and values less than 0.05
were considered significant.
RESULTS
Patient characteristics
The baseline characteristics of the patients are shown in
Table 1. Sixty-three (47%) patients were male. The median
age was 63 yr. The predominant pathology was adenocarci-
noma (99 patients, 74%). Never-smokers comprised 52%
of patients. The proportions of stage I, II, and III cancers were
36%, 17%, and 47%, respectively. EGFR mutations were
detected in 24% of patients. The mutation rate was higher
in never-smokers than in smokers (33% vs. 14%, respective-
ly; p=0.009) and in females than in males (31% vs. 16%,
respectively; p=0.036). The frequency of EGFR mutations
was not significantly greater in younger (<50 yr) than in older
(≥50 yr) patients (33% vs. 23%, respectively; p=0.322) or
in patients with adenocarcinomas than in those with other
histologies (27% vs. 5%, respectively; p=0.139). KRAS muta-
tions were detected in 16 of 133 (12%) patients, and were
detected more frequently in males than in females (19% vs.
6%, respectively; p=0.018), more often in smokers than in
never-smokers (19% vs. 6%, respectively; p=0.022). Neither
pathology nor age was a significant factor predicting the pres-
ence of KRAS mutations.
Characteristic N (%)
Age (yr)
Median 63
Range 38-89
Sex
Male 63 (47)
Female 70 (53)
Smoking history
Ever-smoker 64 (48)
Never-smoker 69 (52)
Histology
Adenocarcinoma 99 (74)
Other 34  (26)
Histology according to BAC features
Adenocarcinoma with BAC features 17 (13)
Other 116 (87)
Stage
I 48 (36)
II 22 (17)
III 63 (47)
Table 1. Patient characteristicsClinical Features Reflect Exon Sites of EGFR Mutations 395
Types of EGFR and KRAS mutations
Mutations in codons 12 and 13 of KRAS were found in 16
patients and one patient, respectively (one patient had a dou-
ble mutation). G12D (nine patients) was the most common
mutation (one patient also carried G13D). G12C (two pati-
ents) and G12V (two patients) were detected. One patient
carried G12S, and G12A was observed in two patients. There
was no mutation in codon 61. No patient had a tumor in
which both EGFR and KRAS were mutated.
EGFR mutations were detected in 32 patients (Table 2).
Mutations in exon 20 were most frequent (16 patients). P772_
H773insPR in exon 20 was detected in 11 patients. All muta-
tions present in exon 19 were deletion types; del K745_E749
(four patients), del A750_K757 (one patient), del E746_A750
(one patient), and del L747_P753 (one patient). L858R in
exon 21 was found in six patients. One patient carried two
mutations, in exon 18 and exon 21 (G719D and L861Q,
respectively).
Multinomial logistic regression was used to compare two
subgroups of EGFR mutations in the different exons with
those of the wild type (the double mutation in exons 18 and
21 was considered to be a mutation in exon 18). The odds
ratio was calculated with the wild type as the reference group.
Non-small-cell lung cancer with a mutation in exon 18 or 19
was positively associated with never-smokers (OR, 10.7; p=
0.027) and BAC features (OR, 5.93; p=0.016). All cases with
a mutation in exon 18 or 19 were adenocarcinoma. Females
also showed a positive relationship with mutations in exons
18 or 19, but the association was not significant (OR, 4.41;
p=0.068). Compared with mutations in exons 18-19, muta-
Exon 18-19 mutation
(N=10)
OR (p value)
Exon 20-21 mutation
(N=22)
OR (p value)
Female 4.41 (0.068) 1.93 (0.175)
Young age (<50 yr) 1.85 (0.467) 1.65 (0.430)
Never-smoker 10.7 (0.027) 2.09 (0.129)
BAC features 5.93 (0.016) 0.34 (0.309)
Table 3. Clinical characteristics according to exonal sites of
EGFR mutations
Exon 18 Exon 19 Exon 20 Exon 21
G719D(1)* del K745_E749(4) L799R(1) L861Q(1)*
G719C(1) del E746_E750(1) D807N(1) L858R(6)
K713F(1) del L747_P753(1) T805I(1)
del A750_K757(1) P772_H773insPR(11)
H773_V774insH(1)
S768_V769insAWT(1)
Table 2. Types of EGFR mutations. Numbers in parentheses
indicate the numbers of patients with the mutations. (*) one pa-
tient carried two different mutations
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Fig. 1. Kaplan-Meier plots of overall survival according to EGFR
mutations.
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Fig. 2. Kaplan-Meier plots of (A) disease-free survival and (B) overall survival according to the presence of EGFR mutations in exons 18-19.
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tions in exons 20-21 did not show a significant association
with never-smokers or females (Table 3).
Types of EGFR mutations were associated with disease-
free and overall survival
The median follow-up time was 29 months. By May 2005,
the numbers of observed relapses and deaths were 83 and 54,
respectively. The presence of EGFR mutations was not sig-
nificantly associated with overall survival (p=0.27) (Fig. 1).
Interestingly, we found that the five-year survival rate (5YSR)
for mutations in exons 18-19 (5YSR, 100%) was higher than
that for mutations in exons 20-21 (5YSR, 57%) or the wild
type (5YSR, 44%; p=0.056). For the analysis of different
demographic features and statistical power, the types of muta-
tions in the different exons were collapsed to mutations in
exons 18-19 and others. There was no significant difference
in disease-free survival between these two groups; the median
disease-free survival was 45 months for patients with mutant
exons 18-19 and 26 months for the others (p=0.143) (Fig.
2A). The presence of a mutation in exons 18-19 was a sig-
nificant prognostic factor for overall survival (5YSR, 100%
vs. 47% in patients without such mutations; p=0.021) (Fig.
2B). The KRAS mutation was not a prognostic factor for dis-
ease-free survival or overall survival (p=0.371 and 0.742, res-
pectively) (Fig. 3).
We applied recursive partitioning to construct a classifi-
cation model for survival (Fig. 4A). Age (<50 vs. ≥50 yr),
stage, pathology, KRAS mutation, and exon site of EGFR
mutation (designated Ex 18, Ex 19, Ex 20, Ex 21, and wild
type) were used in the model. The standardized event rate,
which is a special case of the event rate in the Poisson model
for censored data with exponential scaling, was set to one for
the entire sample at the first node. The classification tree start-
ed at the top where 54 of the 133 total patients developed
events. The model chose the exon site of the mutation for
the first split and cancer stage for the second. The resulting
terminal nodes (node 1, node 2, and node 3) were groups
with mutations in Ex 18-19, stage I-II, and stage III accord-
ing to increasing standardized event rates (0.17, 0.89, and
1.41, respectively). The observed five-year survival rates were
100%, 53%, and 46%, respectively. Fig. 4B shows the Ka-
plan-Meier estimates of overall survival according to each node.
The survival rates of the three groups were significantly dif-
ferent (p=0.026).
DISCUSSION
Recently, the BR.21 trial reported the survival benefits of
erlotinib as a second-line therapy, in which the subgroup of
P
r
o
b
a
b
i
l
i
t
y
 
(
%
)
100
75
50
25
0 20 40 60 80 100
Months
Overall survival
RAS mutation -
Fig. 3. Overall survival according to KRAS mutations by Kaplan-
Meier method.
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Fig. 4. (A) The final tree fitted by recursive partitioning using an exponential scaling method. The standardized event rate and events/total
number of observations per subgroup are given. (B) Kaplan-Meier plots of overall survival according to three different nodes.
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Node 3never-smokers displayed better survival (11). The results of
a subset analysis in the TRIBUTE trial showed a survival gain
for never-smokers when treated with chemotherapy and erlo-
tinib (24). It seems clear that some subgroups might respond
to TKI or show a survival benefit.
Most studies have based their analyses on the assumption
that all types of EGFR mutations have the same prognostic
significance in terms of overall survival. Mutations in exon
18 are associated with the P-loop. Deletion of exon 19 occurs
just downstream from a lysine residue at a critical position
for ATP binding, and L858R mutations occur adjacent to
the DFG motif, which stabilizes the A-loop. All types of
mutations, including these mutations, could lead to confor-
mational changes that might theoretically result in a response
to TKI (9, 25). However, in most studies, no structural mod-
eling or biochemical analysis has been performed for novel
mutations. Furthermore, not all investigators analyzed exons
18-21 of EGFR (13, 14).
Shigematsu et al. reported a mutation in exon 20 that is
found in 9% of patients with EGFR mutations (26). In our
study, 16 of 32 patients carried a mutation in exon 20, which
is a relatively high proportion compared with those reported
previously. It should be noted that there was a preponderance
of early-stage cancers and adenocarcinomas in our study pop-
ulation. Our results indicate that mutations in exon 20 were
more common in females (10 patients), never-smokers (10
patients), and those with adenocarcinomas (13 patients), which
is consistent with the known demographic features of EGFR
mutations. Racial differences could be a possible cause.
The proportions of mutations in exons 18-19 among EGFR
mutants have varied in previous studies. Cappuzzo et al. re-
ported a frequency of 47% (seven of 15 mutations), and found
that gene amplification is a more important factor in survival
than is mutation (14). The BR.21 trial showed that 40% of
mutations occurred in exons 18-19 (16 of 40 mutations) (10).
Of the other studies that showed a survival benefit for TKI,
Han et al. reported that 65% of mutations occurred in exons
18-19 (11 of 17 mutations) and Eberhard et al. reported that
69% of mutations occurred in exons 18-19 (20 of 29 muta-
tions) (12, 13). In another study, which reported a better res-
ponse in patients with deletion mutations (16 patients with
deletions in exons 18-19 mutation) and better survival in
patients with mutant EGFR, exon 18-19 mutations com-
prised 61% of all mutations (27). The proportion of exon 18-
19 mutations appears to be higher in studies that show a sur-
vival benefit for TKI in patients with EGFR mutations (10,
12-14, 27). Therefore, the inconsistent results of previous
studies regarding EGFR mutations might be due to the vary-
ing proportions of exon 18-19 mutations among the mutant
EGFRs examined. This could lead to different analyses of the
putative ‘EGFR mutation’ as a prognostic factor. The current
study suggests that the exonal site of EGFR muations and
stage were more important prognostic factors than pathology.
Our results also show a positive association between never-
smokers and exon 18-19 mutations, compared with exon 20-
21 mutations. The TRIBUTE molecular study found that
EGFR mutations were a prognostic factor in NSCLC, but
the BR.21 study did not (10). Both studies reported better
survival for never-smokers. These studies did not undertake
molecular analysis of all patients. Therefore, the discrepancy
for EGFR mutations but the consistency for never-smokers
could be explained if never-smokers have a greater tendency
to carry exon 18-19 mutations. In addition, different demo-
graphic features according to BAC feature and smoking his-
tory may explain the results of another study to observe bet-
ter response in the BAC subtype and never-smoker (20).
Most previous studies for EGFR mutations examined pa-
tients with advanced-stage cancers, whereas we performed
this study on localized tumors. The subgroup analysis of
TRIBUTE showed that EGFR mutations did not confer a
survival benefit in combination with chemotherapy, but did
confer better survival with no relationship to the type of treat-
ment (12). This suggests that EGFR mutations themselves
are a prognostic factor for survival. We postulated that sur-
vival differences caused by EGFR mutations could be observed
in resected NSCLC. Shigematsu et al. found no survival differ-
ence according to the presence of EGFR mutations, which
was consistent with our study (26). They evaluated the sur-
vival outcome between the L858R mutation and exon 19
mutation. Contrasting with our results, patients with the
L858R mutation appeared to achieve better survival although
the difference was not statistically significant (p=0.05). It
should be considered that this study involved a heterogeneous
group including advanced-stage cancers and presented the
results of univariate analysis. In addition, its study population
consisted of various ethnicities and the proportion of adeno-
carcinoma was lower than our study. These differences might
have led to different results for overall survival according to
mutational types of EGFR. In the current study, some patients
(n=15) received gefitinib in relapse. There was no difference
in terms of response to gefitinib according to mutational sites
(data not shown). Even when these patients were excluded
in survival analysis, patients with mutations in exon 18-19
showed better overall survival (p=0.045).
It is not clear whether the various types of mutant EGFRs
affect the survival of patients with tumors by different sig-
nal transduction pathways. Although both deletion of exon
19 and L858R mutation activated EGFR by a common path-
way (AKT and STAT), EGF-induced phosphorylation of
Y845, one of autophosphorylation sites in EGFR, was observed
only in cell lines with the L858R mutation (28). Some inves-
tigators have reported that phosphorylated Y845 regulates
cell survival by another downstream pathway (29). We hypo-
thesize that mutations on either side of the  C-helix of EGFR
(mutations in exons 18-19 and exons 20-21) cause different
conformational changes in EGFR that lead to the activation
of various downstream pathways. A definitive explanation
of the variations in survival according to the exon site of the
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In conclusion, the present study demonstrated better sur-
vival for NSCLC patients with mutations in exons 18-19.
This suggests that survival may differ according to the exon
sites of the EGFR mutation. Our results, together with those
of previous studies, should be interpreted with caution because
the numbers of patients with mutations were small and the
studies were performed retrospectively. Further laboratory
studies of the downstream pathways involved and analysis
of the actual crystal structures of the EGFR mutants are antic-
ipated. A large prospective study is required to confirm these
findings.
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